アリイズミ　シユンイチ   Ariizumi Shiyun'ichi   有泉　俊一    所属   医学部 医学科（東京女子医科大学病院）    職種   准教授
論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: A prospective multicenter study.
掲載誌名	正式名：International journal of cancer 略　 称：Int J Cancer ISSNコード：10970215/00207136
掲載区分	国外
巻・号・頁	147(9),pp.2578-2586
著者・共著者	Okada Rei, Otsuka Yuichiro, Wakabayashi Taiga, Shinoda Masahiro, Aoki Takeshi, Murakami Masahiko, Arizumi Shunichi, Yamamoto Masakazu, Aramaki Osamu, Takayama Tadatoshi, Wakiyama Shigeki, Yanaga Katsuhiko, Amikura Katsumi, Kaneko Hironori, Shimada Hideaki
発行年月	2020/11
概要	Serum autoantibodies have been reported to react with tumor-associated antigen (TAA) in various cancers. This multicenter study evaluated the diagnostic and prognostic value of six autoantibodies against a panel of six hepatocellular carcinoma (HCC)-associated antigens, including Sui1, p62, RalA, p53, NY-ESO-1 and c-myc. A total of 160 patients with HCC and 74 healthy controls were prospectively enrolled from six institutions. Serum antibody titers were determined by enzyme-linked immunosorbent assays. The sensitivities were 19% for Sui1, 18% for p62, 17% for RalA, 11% for p53, 10% for NY-ESO-1 and 9% for c-myc. Overall sensitivity of the TAA panel (56%) was higher than that of α-fetoprotein (41%, P < .05). The combined sensitivity of the TAA panel and α-fetoprotein was significantly higher than that of α-fetoprotein alone (P < .001). The difference in overall survival of TAA panel-positive and panel-negative patients was significant when the Stage I/II patients were combined (P = .023). Overall survival was worse in NY-ESO-1 antibody-positive than in NY-ESO-1 antibody-negative patients (P = .002). Multivariate analysis found that positivity for the TAA panel was independently associated with poor prognosis (P = .030). This TAA panel may have diagnostic and prognostic value in the patients with HCC.
DOI	10.1002/ijc.33165
PMID	32574375